AI-Enabled Bioweapons Risk a Wake-Up Call for Biotech

MIT Technology Review warns that the threat of AI-enabled bioweapons should serve as a wake-up call for the biotechnology industry. The concern is no longer purely theoretical. Leading AI figures, including Anthropic CEO Dario Amodei and OpenAI CEO Sam Altman, have publicly cautioned that advanced models could help bad actors design dangerous biological agents. Even if such scenarios remain difficult to execute, the pace of AI progress means the window for preparation may be narrow. The article argues that biotech firms cannot treat security as someone else's problem. Companies working with synthetic DNA, protein design, lab automation, and biological data could become chokepoints, or unwitting enablers, if they lack strong safeguards. That means improving screening of orders and customers, monitoring for suspicious patterns, securing sensitive datasets, and training staff to recognize misuse. Governance is equally important. Voluntary best practices help, but they can be uneven across countries and smaller labs. The article calls for coordinated action among AI labs, biotech companies, governments, and scientific institutions. Shared standards for risk assessment, red-teaming, and reporting could make it harder for malicious actors to exploit gaps. International cooperation will be necessary because biological threats do not respect borders, and a weak link in one country can affect global safety. There is also a tension between security and open science. Too little openness can slow beneficial research, while too much can create risks. The goal should be responsible access: enabling legitimate discovery while adding friction for dangerous requests. That may require new technical tools, such as better DNA synthesis screening and AI models trained to refuse harmful biological instructions. The biotech industry has long dealt with safety and ethics, but AI changes the scale and speed of potential threats. The article's message is urgent: waiting for a crisis would be a mistake. Proactive security, transparent governance, and cross-sector collaboration are needed before AI-enabled biological risks move from speculation to reality.